Pharmaceuticals 13 March 2026 - 26 May 2026

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote
·······

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote

Ligand Pharmaceuticals shares rose 1.4% to $233.11 by early afternoon Tuesday, bucking a sharp drop in biotech ETFs. Investors traded on anticipation of management meetings and the pending $739 million XOMA Royalty acquisition. XOMA shares slipped 0.3%. The Ligand-XOMA deal still requires shareholder approval and could face delays.
June 2, 2026
Lexaria Gets Attention with GLP-1 Test on Deck
····

Lexaria Gets Attention with GLP-1 Test on Deck

Lexaria Bioscience shares closed at $0.65 on Friday, up 7.33%, and resume Nasdaq trading Tuesday after the holiday. The company plans to start dosing in a human study comparing its DehydraTECH-semaglutide pills to Novo Nordisk’s Wegovy in mid-June. Lexaria extended a pharma partnership deal through the end of 2026. Its latest filing cited “substantial doubt” about ongoing operations without new funding.
May 26, 2026
60 Degrees Pharma Nears FDA Deadline in Thin Holiday Trading
····

60 Degrees Pharma Nears FDA Deadline in Thin Holiday Trading

60 Degrees Pharmaceuticals (SXTP) closed unchanged at $1.48 Tuesday as investors awaited an FDA decision deadline on its Australian Chestnut Extract NDIN. The stock rose 6.5% last week but remains thinly traded. First-quarter net product revenue fell to $162,000, with a net loss of $2.21 million. Eric Francois joined the board on May 13, according to a May 18 filing.
May 25, 2026
CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes
····

CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes

CervoMed Inc. shares fell 11% this week, closing at $3.06 Friday after a first-quarter update highlighted funding needs for its planned Phase 3 dementia trial. The company reported $12.9 million in cash as of March 31, with a runway into September 2026. No grant revenue was recorded in Q1, and net loss widened to $8 million. Nasdaq is closed Monday for Memorial Day; trading resumes Tuesday.
May 23, 2026
GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist
·····

GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist

Structure Therapeutics shares climbed 5.3% to $38.79 in late New York trading Thursday, with no new company release in the past two days. The move followed Eli Lilly’s report of strong weight-loss data for its obesity drug, which kept focus on the sector. Structure’s aleniglipron showed 16.3% placebo-adjusted mean weight loss at 44 weeks in Phase 2. Monashee Investment Management trimmed its stake in the first quarter, SEC filings show.
May 21, 2026
Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders
····

Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders

Bright Minds Biosciences shares jumped 11.1% to $82.78 after Piper Sandler raised its price target to $220 and reiterated an “Overweight” rating. The company reported C$309.7 million in cash at March 31, up from C$82.9 million in September, and a wider net loss. Lead drug BMB-101 completed Phase 1 and reported Phase 2 data for epilepsy and absence seizures.
May 21, 2026
GSK Stock Goes Ex-Dividend Today: Why the 17p Payout Comes With a Bigger Pipeline Test
····

GSK Shares Face Monday Test After Dividend Hit, China Drug Deal And Buyback

GSK shares closed Friday at 1,862.5p, down 0.5% on the day but up 1.1% for the week, as the FTSE 100 ended a weak session. Trading volume reached 11.08 million shares. The stock went ex-dividend Thursday and faces scrutiny after a China hepatitis B deal and the launch of a final buyback tranche. Investors remain cautious following GSK’s mixed first-quarter results.
May 16, 2026
GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus
·····

GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus

GSK has signed an exclusive deal with Sino Biopharmaceutical’s CTTQ unit to launch hepatitis B drug candidate bepirovirsen in China, gaining access to over 5,000 medical centres. CTTQ will handle importation, distribution, and promotion, while GSK retains regulatory control. Bepirovirsen is not yet approved anywhere. Financial terms were not disclosed.
May 13, 2026
GSK Wins Paxil Trademark Fight in India, But Its Bigger Test Is Still Ahead
····

GSK Wins Paxil Trademark Fight in India, But Its Bigger Test Is Still Ahead

The Bombay High Court ordered Shreya Life Sciences to remove its registration of the Paxil trademark, siding with Glaxo Group Limited, part of GSK. The court found Shreya had not used the mark since registering it in 2005. GSK’s ADRs fell 1.2% to $51.01 in early New York trading. Investors remain focused on GSK’s vaccine and HIV businesses rather than the trademark ruling.
May 4, 2026
GSK Stock Gets Fresh Catalyst as UK Clears Lynavoy and Pipeline Pressure Builds
···

GSK Stock Gets Fresh Catalyst as UK Clears Lynavoy and Pipeline Pressure Builds

Britain’s MHRA approved GSK’s Lynavoy for adults with primary biliary cholangitis, shortly after GSK licensed global rights to Alfasigma. The approval triggers a $20 million payment to GSK under the deal. Lynavoy, an oral drug for severe itch in PBC, met key goals in a phase 3 trial of 238 patients. GSK reported first-quarter sales of £7.63 billion and core operating profit of £2.65 billion.
May 1, 2026
GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
·······

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake

GSK completed a reshaping of ViiV Healthcare’s ownership on April 1, with Shionogi raising its stake to 21.7% after Pfizer exited the HIV-focused venture. ViiV issued new shares to Shionogi for $2.125 billion and cancelled Pfizer’s holding. GSK retained a 78.3% majority and took a $250 million special dividend. The deal extinguished a put option liability tied to the old structure.
April 2, 2026
GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake
···

GSK plc Completes ViiV Healthcare Shake-Up as Pfizer Exits, Shionogi Lifts Stake

Shionogi increased its stake in ViiV Healthcare to 21.7% as Pfizer exited, leaving GSK with a 78.3% majority. ViiV issued new shares to Shionogi for $2.125 billion and paid Pfizer $1.875 billion. GSK received a $250 million special dividend and removed an accounting liability tied to Pfizer’s exit. The transaction followed Chinese approval of GSK’s asthma drug Exdensur.
April 1, 2026
GSK plc wins China approval for Exdensur as hepatitis B drug bepirovirsen enters review
···

GSK plc wins China approval for Exdensur as hepatitis B drug bepirovirsen enters review

China approved GSK’s asthma drug Exdensur for patients 12 and older and accepted its hepatitis B candidate bepirovirsen for regulatory review, the company said Monday. Exdensur’s approval followed trials showing it reduced annual asthma attacks by up to 58% versus placebo. The drug will compete with Dupixent and Xolair. Bepirovirsen targets chronic hepatitis B, where current treatments rarely clear the virus.
March 30, 2026
GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects
···

GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects

GSK shares rose 0.54% to 2,056 pence in London after the European Medicines Agency agreed to review its experimental hepatitis B drug, bepirovirsen. The company said Phase III trials showed higher functional cure rates when bepirovirsen was added to standard care. The drug is not yet approved. JPMorgan maintained a sell rating, with a target price near current levels.
March 27, 2026
GSK Stock Price Today: Shares Rise After FDA Approval of Lynavoy for Rare Liver-Disease Itch
···

GSK Stock Price Today: Shares Rise After FDA Approval of Lynavoy for Rare Liver-Disease Itch

GSK shares rose 0.6% after the FDA approved Lynavoy, the first U.S. drug specifically for severe itching in primary biliary cholangitis. Alfasigma agreed to pay GSK $300 million upfront for global rights to the drug, plus $100 million more on U.S. approval. GSK and Alfasigma have not disclosed launch pricing or availability. Lynavoy approval follows recent regulatory wins for GSK.
March 19, 2026
1 2 3 4